ArticleTranslational vision science & technology2023
Identifying, Understanding, and Addressing Disparities in Glaucoma Care in the United States.
Article in Translational vision science & technology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 37 citations in OpenAlex.
- Patient and Neighborhood Factors Influencing Glaucoma Medication Adherence.Journal of glaucoma · 2026Article
- Artificial Intelligence-Driven Multimodal Prediction of 10-Year Incident Glaucoma Integrating Genetic and Deep Learning-Derived Imaging Features.Ophthalmology science · 2026Article
- Wirelessly Interrogated, Implantable Capacitive MEMS Sensors for Continuous Intraocular Pressure Monitoring.Sensors (Basel, Switzerland) · 2026Article
- Deep-learning-derived glaucoma-related endophenotypes enable novel genome-wide genetic and functional discovery.Research square · 2026Article
- Utility of optometrist referrals for glaucoma evaluation in a young adult population.Clinical & experimental optometry · 2026Article
- Deep-learning-derived glaucoma-related endophenotypes enable novel genome-wide genetic and functional discovery.medRxiv : the preprint server for health sciences · 2025Article
- Generative Artificial Intelligence for Retinal Image Translation to Improve Glaucoma Screening With Deep Learning.Translational vision science & technology · 2025Article
- Clinical Benefits of Preservative-Free Treatment for Glaucoma with a Focus on Preservative-Free Latanoprost.Ophthalmology and therapy · 2025Review
- Acute Angle Closure Incidence in a Large Countywide Safety Net Teleretinal Screening Program.JAMA ophthalmology · 2025Article
- Outcomes of Trabeculectomy With Mitomycin C in Patients of Hispanic vs European Descent.JAMA ophthalmology · 2025Article
- Longitudinal Trends in Resource Utilization Associated With Newly Diagnosed Primary Angle Closure Glaucoma in the United States.Journal of glaucoma · 2025Article
- Understanding Glaucoma: Why it Remains a Leading Cause of Blindness Worldwide.Klinische Monatsblatter fur Augenheilkunde · 2025Review
- Emerging trends in long-acting sustained drug delivery for glaucoma management.Drug delivery and translational research · 2025Review
- Latin American Prevalence of Glaucoma: A Systematic Review and Meta-Analysis.Vision (Basel, Switzerland) · 2025Review
- The Association of Social Determinants of Health on Monitoring for Disease Progression Among Patients With Primary Open-Angle Glaucoma.Translational vision science & technology · 2025Article
- Outcomes of Glaucoma Referrals in Adults Aged 18 to 40 Years.JAMA network open · 2025Article
- Amniotic Membrane Transplantation: Clinical Applications in Enhancing Wound Healing and Tissue Regeneration.Advances in experimental medicine and biology · 2025Review
- Relationship Between Glaucoma and Chronic Stress Quantified by Allostatic Load Score in the All of Us Research Program.American journal of ophthalmology · 2025Article
- Validation of a Novel Low-Cost Glaucoma Risk Calculator for Community-Based Screening in High-Risk Populations.Clinical ophthalmology (Auckland, N.Z.) · 2025Article
- Exploring Glaucoma: From Pathogenesis to Emerging Diagnostic and Management Strategies.Journal of ophthalmology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Glaucoma is the leading cause of irreversible blindness worldwide, currently affecting around 80 million people. Glaucoma prevalence is rapidly rising in the United States due to an aging population. Despite recent advances in the diagnosis and treatment of glaucoma, significant disparities persist in disease detection, management, and outcomes among the diverse patient populations of the United States. Research on disparities is critical to identifying, understanding, and addressing societal and healthcare inequalities. Disparities research is especially important and impactful in the context of irreversible diseases such as glaucoma, where earlier detection and intervention are the primary approach to improving patient outcomes. In this article, we first review recent studies identifying disparities in glaucoma care that affect patient populations based on race, age, and gender. We then review studies elucidating and furthering our understanding of modifiable factors that contribute to these inequities, including socioeconomic status (particularly age and education), insurance product, and geographic region. Finally, we present work proposing potential strategies addressing disparities in glaucoma care, including teleophthalmology and artificial intelligence. We also discuss the presence of non-modifiable factors that contribute to differences in glaucoma burden and can confound the detection of glaucoma disparities. Translational Relevance: By recognizing underlying causes and proposing potential solutions, healthcare providers, policymakers, and other stakeholders can work collaboratively to reduce the burden of glaucoma and improve visual health and clinical outcomes in vulnerable patient populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.